TLC-ART can transform first-line 3 drugs TLD (tenofovir/lamivudine/tenofovir) as one long-acting injectable lasting 1 month in nonhuman primates
In a significant pharmaceutical breakthrough, researchers at our laboratory have successfully developed an innovative long-acting injectable version of the antiretroviral drug combination known as TLD, comprising tenofovir, lamivudine, and dolutegravir. This formulation, endorsed as the first-line treatment for HIV by the World Health Organization, employs advanced drug-combination nanoparticle technology. This technology significantly extends the duration of the drug’s presence in the bloodstream to up to one month with just a single injection. The groundbreaking results of this research, conducted on nonhuman primates for now, were recently published in the esteemed journal AIDS, garnering considerable attention and acclaim within the global AIDS research community.
The composition was made of generic and approved components, with public funding, and therefore costs should be limited, which can be of interest to low-mid income countries.
Additionally, leveraging the onboard tenofovir component, long-acting TLD holds the potential for coverage in people living with HIV and HBV.
NEWS: